{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:52:48Z","timestamp":1791928368588,"version":"4.3.4"},"reference-count":81,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T00:00:00Z","timestamp":1616371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","award":["MIRAI"],"award-info":[{"award-number":["MIRAI"]}],"id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosbiology.org"],"crossmark-restriction":false},"short-container-title":["PLoS Biol"],"abstract":"<jats:p>The scientific community is focused on developing antiviral therapies to mitigate the impacts of the ongoing novel coronavirus disease 2019 (COVID-19) outbreak. This will be facilitated by improved understanding of viral dynamics within infected hosts. Here, using a mathematical model in combination with published viral load data, we compare within-host viral dynamics of SARS-CoV-2 with analogous dynamics of MERS-CoV and SARS-CoV. Our quantitative analyses using a mathematical model revealed that the within-host reproduction number at symptom onset of SARS-CoV-2 was statistically significantly larger than that of MERS-CoV and similar to that of SARS-CoV. In addition, the time from symptom onset to the viral load peak for SARS-CoV-2 infection was shorter than those of MERS-CoV and SARS-CoV. These findings suggest the difficulty of controlling SARS-CoV-2 infection by antivirals. We further used the viral dynamics model to predict the efficacy of potential antiviral drugs that have different modes of action. The efficacy was measured by the reduction in the viral load area under the curve (AUC). Our results indicate that therapies that block de novo infection or virus production are likely to be effective if and only if initiated before the viral load peak (which appears 2\u20133 days after symptom onset), but therapies that promote cytotoxicity of infected cells are likely to have effects with less sensitivity to the timing of treatment initiation. Furthermore, combining a therapy that promotes cytotoxicity and one that blocks de novo infection or virus production synergistically reduces the AUC with early treatment. Our unique modeling approach provides insights into the pathogenesis of SARS-CoV-2 and may be useful for development of antiviral therapies.<\/jats:p>","DOI":"10.1371\/journal.pbio.3001128","type":"journal-article","created":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T13:22:44Z","timestamp":1616419364000},"page":"e3001128","update-policy":"https:\/\/doi.org\/10.1371\/journal.pbio.corrections_policy","source":"Crossref","is-referenced-by-count":150,"title":["A quantitative model used to compare within-host SARS-CoV-2, MERS-CoV, and SARS-CoV dynamics provides insights into the pathogenesis and treatment of SARS-CoV-2"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6626-316X","authenticated-orcid":true,"given":"Kwang Su","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1185-3987","authenticated-orcid":true,"given":"Keisuke","family":"Ejima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1474-5348","authenticated-orcid":true,"given":"Shoya","family":"Iwanami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1720-3942","authenticated-orcid":true,"given":"Yasuhisa","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Koizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Asai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Nakaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Watashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Aihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8545-5212","authenticated-orcid":true,"given":"Robin N.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5307-8934","authenticated-orcid":true,"given":"Ruian","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2455-0002","authenticated-orcid":true,"given":"Alan S.","family":"Perelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1780-350X","authenticated-orcid":true,"given":"Shingo","family":"Iwami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,3,22]]},"reference":[{"issue":"13","key":"pbio.3001128.ref001","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","article-title":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia","volume":"382","author":"Q Li","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"pbio.3001128.ref002","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3390\/jcm9020498","article-title":"Novel coronavirus outbreak in Wuhan, China, 2020: intense surveillance is vital for preventing sustained transmission in new locations.","volume":"9","author":"RN Thompson","year":"2020","journal-title":"J Clin Med."},{"issue":"5","key":"pbio.3001128.ref003","doi-asserted-by":"crossref","first-page":"362","DOI":"10.7326\/M20-3012","article-title":"Prevalence of asymptomatic SARS-CoV-2 infection: a narrative review","volume":"173","author":"DP Oran","year":"2020","journal-title":"Ann Intern Med"},{"issue":"6","key":"pbio.3001128.ref004","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1473-3099(20)30243-7","article-title":"Estimates of the severity of coronavirus disease 2019: a model-based analysis.","volume":"20","author":"R Verity","year":"2020","journal-title":"Lancet Infect Dis."},{"issue":"3","key":"pbio.3001128.ref005","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.","volume":"30","author":"M Wang","year":"2020","journal-title":"Cell Res"},{"key":"pbio.3001128.ref006","article-title":"Multidrug treatment with nelfinavir and cepharanthine against COVID-19.","author":"H Ohashi","year":"2020","journal-title":"bioRxiv."},{"issue":"3","key":"pbio.3001128.ref007","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.cell.2020.06.011","article-title":"A SARS-CoV-2 infection model in mice demonstrates protection by neutralizing antibodies","volume":"182","author":"AO Hassan","year":"2020","journal-title":"Cell"},{"issue":"7824","key":"pbio.3001128.ref008","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41586-020-2324-7","article-title":"Respiratory disease in rhesus macaques inoculated with SARS-CoV-2","volume":"585","author":"VJ Munster","year":"2020","journal-title":"Nature"},{"issue":"6494","key":"pbio.3001128.ref009","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1126\/science.abb7314","article-title":"Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model","volume":"368","author":"B Rockx","year":"2020","journal-title":"Science"},{"issue":"7824","key":"pbio.3001128.ref010","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41586-020-2423-5","article-title":"Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2","volume":"585","author":"BN Williamson","year":"2020","journal-title":"Nature"},{"issue":"15","key":"pbio.3001128.ref011","first-page":"1488","article-title":"Epidemiologic features and clinical course of patients infected with SARS-CoV-2","volume":"323","author":"BE Young","year":"2020","journal-title":"Singapore. JAMA."},{"issue":"12","key":"pbio.3001128.ref012","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1056\/NEJMc2001737","article-title":"SARS-CoV-2 viral load in upper respiratory specimens of infected patients","volume":"382","author":"L Zou","year":"2020","journal-title":"N Engl J Med"},{"issue":"13","key":"pbio.3001128.ref013","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.3346\/jkms.2020.35.e142","article-title":"Clinical course and outcomes of patients with severe acute respiratory syndrome coronavirus 2 infection: a preliminary report of the first 28 patients from the Korean Cohort Study on COVID-19.","volume":"35","author":"ES Kim","year":"2020","journal-title":"J Korean Med Sci"},{"issue":"7809","key":"pbio.3001128.ref014","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41586-020-2196-x","article-title":"Virological assessment of hospitalized patients with COVID-2019.","volume":"581","author":"R W\u00f6lfel","year":"2020","journal-title":"Nature"},{"issue":"6","key":"pbio.3001128.ref015","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S1473-3099(20)30200-0","article-title":"Clinical and virological data of the first cases of COVID-19 in Europe: a case series","volume":"20","author":"FX Lescure","year":"2020","journal-title":"Lancet Infect Dis."},{"issue":"7","key":"pbio.3001128.ref016","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.3346\/jkms.2020.35.e86","article-title":"Viral load kinetics of SARS-CoV-2 infection in first two patients in Korea.","volume":"35","author":"JY Kim","year":"2020","journal-title":"J Korean Med Sci."},{"issue":"9","key":"pbio.3001128.ref017","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/psp4.12543","article-title":"Timing of antiviral treatment initiation is critical to reduce SARS-CoV-2 viral load.","volume":"9","author":"A Gon\u00e7alves","year":"2020","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"47","key":"pbio.3001128.ref018","doi-asserted-by":"crossref","first-page":"eabc7112","DOI":"10.1126\/sciadv.abc7112","article-title":"Potency and timing of antiviral therapy as determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory response.","volume":"6","author":"A Goyal","year":"2020","journal-title":"Sci Adv."},{"key":"pbio.3001128.ref019","article-title":"Kinetics of SARS-CoV-2 infection in the human upper and lower respiratory tracts and their relationship with infectiousness.","author":"R Ke","year":"2020","journal-title":"medRxiv."},{"key":"pbio.3001128.ref020","article-title":"Modelling SARS-CoV-2 dynamics: implications for therapy.","author":"KS Kim","year":"2020","journal-title":"medRxiv."},{"issue":"13","key":"pbio.3001128.ref021","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMc1511695","article-title":"Viral load kinetics of MERS coronavirus infection","volume":"375","author":"MD Oh","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"pbio.3001128.ref022","doi-asserted-by":"crossref","first-page":"753","DOI":"10.3201\/eid2504.181595","article-title":"Middle East Respiratory Syndrome coronavirus infection dynamics and antibody responses among clinically diverse patients, Saudi Arabia","volume":"25","author":"HM Al-Abdely","year":"2019","journal-title":"Emerg Infect Dis"},{"issue":"9371","key":"pbio.3001128.ref023","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/S0140-6736(03)13412-5","article-title":"Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study","volume":"361","author":"JS Peiris","year":"2003","journal-title":"Lancet"},{"issue":"1","key":"pbio.3001128.ref024","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nri700","article-title":"Modelling viral and immune system dynamics","volume":"2","author":"AS Perelson","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"pbio.3001128.ref025","article-title":"Success of prophylactic antiviral therapy for SARS-CoV-2: predicted critical efficacies and impact of different drug-specific mechanisms of action.","author":"P Czuppon","year":"2020","journal-title":"medRxiv."},{"key":"pbio.3001128.ref026","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3389\/fmicb.2012.00319","article-title":"Identifying viral parameters from in vitro cell cultures","volume":"3","author":"S Iwami","year":"2012","journal-title":"Front Microbiol"},{"key":"pbio.3001128.ref027","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.antiviral.2016.10.004","article-title":"Modelling Ebola virus dynamics: implications for therapy","volume":"135","author":"A Martyushev","year":"2016","journal-title":"Antiviral Res"},{"issue":"8","key":"pbio.3001128.ref028","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S1473-3099(20)30287-5","article-title":"Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study","volume":"20","author":"Q Bi","year":"2020","journal-title":"Lancet Infect Dis."},{"issue":"1","key":"pbio.3001128.ref029","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1080\/22221751.2020.1729069","article-title":"Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody.","volume":"9","author":"X Tian","year":"2020","journal-title":"Emerg Microbes Infect."},{"key":"pbio.3001128.ref030","volume-title":"Emergence use authorization 090.","author":"RD Hinton","year":"2021"},{"issue":"6","key":"pbio.3001128.ref031","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/jmv.25729","article-title":"A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus\u2014a possible reference for coronavirus disease-19 treatment option","volume":"92","author":"TT Yao","year":"2020","journal-title":"J Med Virol"},{"issue":"1","key":"pbio.3001128.ref032","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5582\/bst.2020.01020","article-title":"Drug treatment options for the 2019-new coronavirus (2019-nCoV).","volume":"14","author":"H. Lu","year":"2020","journal-title":"Biosci Trends."},{"issue":"1","key":"pbio.3001128.ref033","doi-asserted-by":"crossref","first-page":"8869","DOI":"10.1038\/s41598-020-65860-x","article-title":"Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs).","volume":"10","author":"RM Hoffmann","year":"2020","journal-title":"Sci Rep."},{"issue":"8","key":"pbio.3001128.ref034","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1073\/pnas.1610197114","article-title":"Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection","volume":"114","author":"Y Koizumi","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"pbio.3001128.ref035","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nm1777","article-title":"Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs","volume":"14","author":"L Shen","year":"2008","journal-title":"Nat Med"},{"issue":"11","key":"pbio.3001128.ref036","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/nrmicro3351","article-title":"A mechanistic theory to explain the efficacy of antiretroviral therapy","volume":"12","author":"SB Laskey","year":"2014","journal-title":"Nat Rev Microbiol"},{"issue":"31","key":"pbio.3001128.ref037","doi-asserted-by":"crossref","first-page":"18754","DOI":"10.1073\/pnas.2008236117","article-title":"Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody","volume":"117","author":"M Asokan","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"30","key":"pbio.3001128.ref038","doi-asserted-by":"crossref","first-page":"18002","DOI":"10.1073\/pnas.2008190117","article-title":"Quantifying the contribution of Fc-mediated effector functions to the antiviral activity of anti-HIV-1 IgG1 antibodies in vivo","volume":"117","author":"P Wang","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"pbio.3001128.ref039","doi-asserted-by":"crossref","first-page":"e20201993","DOI":"10.1084\/jem.20201993","article-title":"Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo","volume":"218","author":"A Sch\u00e4fer","year":"2021","journal-title":"J Exp Med"},{"key":"pbio.3001128.ref040","article-title":"SARS-CoV-2 viral load peaks prior to symptom onset: a systematic review and individual-pooled analysis of coronavirus viral load from 66 studies.","author":"AE Benefield","year":"2020","journal-title":"medRxiv."},{"issue":"5","key":"pbio.3001128.ref041","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/s41591-020-0869-5","article-title":"Temporal dynamics in viral shedding and transmissibility of COVID-19","volume":"26","author":"X He","year":"2020","journal-title":"Nat Med"},{"issue":"1","key":"pbio.3001128.ref042","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/S2666-5247(20)30172-5","article-title":"SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis","volume":"2","author":"M Cevik","year":"2021","journal-title":"Lancet Microbe."},{"issue":"22","key":"pbio.3001128.ref043","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1001\/jama.2020.8259","article-title":"Interpreting diagnostic tests for SARS-CoV-2","volume":"323","author":"N Sethuraman","year":"2020","journal-title":"JAMA"},{"issue":"11","key":"pbio.3001128.ref044","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1093\/cid\/ciaa886","article-title":"Distribution of transmission potential during nonsevere COVID-19 illness","volume":"71","author":"NK Shrestha","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"10","key":"pbio.3001128.ref045","first-page":"994","article-title":"Remdesivir for the treatment of Covid-19\u2014preliminary report. Reply","volume":"383","author":"JH Beigel","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"pbio.3001128.ref046","first-page":"1192","article-title":"Experimental treatment with favipiravir for COVID-19: an open-label control study.","volume":"6","author":"Q Cai","year":"2020","journal-title":"Engineering (Beijing)."},{"issue":"21","key":"pbio.3001128.ref047","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1056\/NEJMc2008043","article-title":"A trial of lopinavir-ritonavir in Covid-19","volume":"382","author":"P Dalerba","year":"2020","journal-title":"N Engl J Med"},{"issue":"25","key":"pbio.3001128.ref048","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1056\/NEJMoa2012410","article-title":"Observational study of hydroxychloroquine in hospitalized patients with Covid-19","volume":"382","author":"J Geleris","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"pbio.3001128.ref049","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"compassionate use of remdesivir for patients with severe Covid-19","volume":"382","author":"J Grein","year":"2020","journal-title":"N Engl J Med"},{"issue":"10236","key":"pbio.3001128.ref050","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Y Wang","year":"2020","journal-title":"Lancet"},{"key":"pbio.3001128.ref051","article-title":"Interleukin-6 receptor antagonists in critically ill patients with Covid-19\u2014preliminary report.","author":"AC Gordon","year":"2021","journal-title":"medRxiv."},{"issue":"11","key":"pbio.3001128.ref052","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jama.2020.16349","article-title":"Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial","volume":"324","author":"CD Spinner","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"pbio.3001128.ref053","doi-asserted-by":"crossref","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.","volume":"56","author":"P Gautret","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"pbio.3001128.ref054","doi-asserted-by":"crossref","first-page":"m1849","DOI":"10.1136\/bmj.m1849","article-title":"Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial.","volume":"369","author":"W Tang","year":"2020","journal-title":"BMJ"},{"issue":"19","key":"pbio.3001128.ref055","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"B Cao","year":"2020","journal-title":"N Engl J Med"},{"key":"pbio.3001128.ref056","doi-asserted-by":"crossref","first-page":"101663","DOI":"10.1016\/j.tmaid.2020.101663","article-title":"Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study.","volume":"34","author":"P Gautret","year":"2020","journal-title":"Travel Med Infect Dis"},{"key":"pbio.3001128.ref057","article-title":"An exploratory randomized controlled study on the efficacy and safety of lopinavir\/ritonavir or arbidol treating adult patients hospitalized with mild\/moderate COVID-19 (ELACOI).","author":"Y Li","year":"2020","journal-title":"medRxiv"},{"issue":"10238","key":"pbio.3001128.ref058","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(20)31042-4","article-title":"Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial","volume":"395","author":"IF Hung","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"pbio.3001128.ref059","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2213-2600(20)30511-7","article-title":"Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial.","volume":"9","author":"PD Monk","year":"2021","journal-title":"Lancet Respir Med."},{"issue":"22","key":"pbio.3001128.ref060","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1001\/jama.2020.8115","article-title":"Randomized clinical trials and COVID-19: managing expectations","volume":"323","author":"H Bauchner","year":"2020","journal-title":"JAMA"},{"issue":"6629","key":"pbio.3001128.ref061","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/387188a0","article-title":"Decay characteristics of HIV-1-infected compartments during combination therapy","volume":"387","author":"AS Perelson","year":"1997","journal-title":"Nature"},{"issue":"3","key":"pbio.3001128.ref062","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1006\/jtbi.2000.1076","article-title":"Modeling plasma virus concentration during primary HIV infection","volume":"203","author":"MA Stafford","year":"2000","journal-title":"J Theor Biol"},{"issue":"35","key":"pbio.3001128.ref063","doi-asserted-by":"crossref","first-page":"17393","DOI":"10.1073\/pnas.1902178116","article-title":"A dynamical motif comprising the interactions between antigens and CD8 T cells may underlie the outcomes of viral infections","volume":"116","author":"S Baral","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"17","key":"pbio.3001128.ref064","doi-asserted-by":"crossref","first-page":"5467","DOI":"10.1073\/pnas.1419162112","article-title":"Post-treatment control of HIV infection","volume":"112","author":"JM Conway","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"pbio.3001128.ref065","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1373\/clinchem.2003.023663","article-title":"Detection of SARS coronavirus in patients with severe acute respiratory syndrome by conventional and real-time quantitative reverse transcription-PCR assays","volume":"50","author":"LL Poon","year":"2004","journal-title":"Clin Chem"},{"issue":"3","key":"pbio.3001128.ref066","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.csda.2006.05.007","article-title":"Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: application to HIV dynamics model.","volume":"51","author":"A Samson","year":"2006","journal-title":"Comput Stat Data Anal."},{"key":"pbio.3001128.ref067","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12977-016-0252-2","article-title":"Quantifying the effect of Vpu on the promotion of HIV-1 replication in the humanized mouse model.","volume":"13","author":"H Ikeda","year":"2016","journal-title":"Retrovirology"},{"issue":"5255","key":"pbio.3001128.ref068","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1126\/science.271.5255.1582","article-title":"HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time","volume":"271","author":"AS Perelson","year":"1996","journal-title":"Science"},{"issue":"5386","key":"pbio.3001128.ref069","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.282.5386.103","article-title":"Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy","volume":"282","author":"AU Neumann","year":"1998","journal-title":"Science"},{"issue":"8","key":"pbio.3001128.ref070","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S1286-4579(02)01603-9","article-title":"Dynamics of hepatitis B virus infection","volume":"4","author":"RM Ribeiro","year":"2002","journal-title":"Microbes Infect"},{"issue":"15","key":"pbio.3001128.ref071","doi-asserted-by":"crossref","first-page":"7590","DOI":"10.1128\/JVI.01623-05","article-title":"Kinetics of influenza A virus infection in humans","volume":"80","author":"P Baccam","year":"2006","journal-title":"J Virol"},{"issue":"117","key":"pbio.3001128.ref072","doi-asserted-by":"crossref","first-page":"20160130","DOI":"10.1098\/rsif.2016.0130","article-title":"Estimating biologically relevant parameters under uncertainty for experimental within-host murine West Nile virus infection.","volume":"13","author":"S Banerjee","year":"2016","journal-title":"J R Soc Interface"},{"issue":"33","key":"pbio.3001128.ref073","doi-asserted-by":"crossref","first-page":"8847","DOI":"10.1073\/pnas.1704011114","article-title":"Zika plasma viral dynamics in nonhuman primates provides insights into early infection and antiviral strategies","volume":"114","author":"K Best","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pbio.3001128.ref074","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.virol.2020.07.015","article-title":"Quantifying the effect of remdesivir in rhesus macaques infected with SARS-CoV-2","volume":"550","author":"HM Dobrovolny","year":"2020","journal-title":"Virology"},{"key":"pbio.3001128.ref075","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.arcontrol.2020.09.006","article-title":"In-host mathematical modelling of COVID-19 in humans.","volume":"50","author":"EA Hernandez-Vargas","year":"2020","journal-title":"Annu Rev Control."},{"key":"pbio.3001128.ref076","volume-title":"Symptoms","author":"Centers for Disease Control and Prevention","year":"2021"},{"key":"pbio.3001128.ref077","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198504184.001.0001","volume-title":"Virus dynamics.","author":"MA Nowak","year":"2000"},{"issue":"4","key":"pbio.3001128.ref078","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/psp4.12500","article-title":"Efficient pharmacokinetic modeling workflow with the MonolixSuite: a case study of remifentanil.","volume":"9","author":"P Traynard","year":"2020","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"21","key":"pbio.3001128.ref079","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1056\/NEJMoa2022926","article-title":"Effect of hydroxychloroquine in hospitalized patients with Covid-19","volume":"383","author":"RECOVERY Collaborative Group","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"pbio.3001128.ref080","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1214\/aos\/1176345462","article-title":"The jackknife estimate of variance.","volume":"9","author":"B Efron","year":"1981","journal-title":"Ann Stat"},{"issue":"3","key":"pbio.3001128.ref081","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1214\/aos\/1176347263","article-title":"A general theory for jackknife variance estimation.","volume":"17","author":"J Shao","year":"1989","journal-title":"Ann Stat"}],"container-title":["PLOS Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pbio.3001128","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T11:25:35Z","timestamp":1724671535000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pbio.3001128"}},"subtitle":[],"editor":[{"given":"Bill","family":"Sugden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,3,22]]},"references-count":81,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pbio.3001128","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.03.23.20040493","asserted-by":"object"}]},"ISSN":["1545-7885"],"issn-type":[{"value":"1545-7885","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,22]]}}}